TCGA-DK-A3IL-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.56767411
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.350
- MYOGENESIS+0.290
- SPERMATOGENESIS+0.240
- APICAL_SURFACE+0.230
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.140
- PANCREAS_BETA_CELLS+0.070
- COAGULATION+0.060
- ESTROGEN_RESPONSE_LATE+0.030
- PEROXISOME+0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- PROTEIN_SECRETION-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.480
- MYC_TARGETS_V1-0.480
- TNFA_SIGNALING_VIA_NFKB-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- OXIDATIVE_PHOSPHORYLATION-0.410
- INFLAMMATORY_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KQ-A41N-01A-11R-A33J-07 | — | — | 0.913 |
| 2 | TCGA-MN-A4N1-01A-11R-A24X-07 | — | cohortA1 | 0.908 |
| 3 | MNG491 | — | — | 0.895 |
| 4 | SRR33346947 | — | — | 0.891 |
| 5 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.886 |
| 6 | MNG1044 | — | — | 0.881 |
| 7 | MNG189 | — | — | 0.880 |
| 8 | SRR1311794 | GTEX | — | 0.879 |
| 9 | SRR602927 | GTEX | — | 0.879 |
| 10 | BS_QC3XCE6X | low-grade glioma | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |